Henlius Capitalizes On Biosimilar Launches

Company Plans To Expand Its Global Footprint and Production Capacity

Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.

Innovation
Henlius is pursuing innovation with its biologics pipeline • Source: Alamy

China’s Shanghai Henlius Biotech said that it “made the most out of recently launched products” in 2020, as the company announced a 546% increase in revenue to RMB587.6m ($89.8m) compared to 2019. The company said that 2020 marked a meaningful year for Henlius, as it “gathered pace in commercialization and continued the momentum for innovation.”

“The overall increase was mainly driven by the sales revenue from the launched products, R&D services provided to customers and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.